SCHEMBL1177685

SCHEMBL1177685

CC(C)[CH]N1CCCCC1

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.32
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3149716 0.97
SCHEMBL6039711 0.80 HSD17B10 (0.38) HSD17B10MAPTHTT
Hydrochloric Acid SCHEMBL27763214 0.78 HSD17B10 (0.36) HSD17B10LMNAHTT
SCHEMBL7139126 0.77
SCHEMBL10588321 0.76
SCHEMBL28351367 0.75 NPC1 (0.32) LMNAMAPT
SCHEMBL10149589 0.75 NPC1 (0.32) LMNAMAPT
SCHEMBL219982 0.71
SCHEMBL4376942 0.71 CHRM5 (0.32)
SCHEMBL219983 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0373549-B1 AMINO ACID DERIVATIVES WITH ENZYME-INHIBITING PROPERTIES, PROCESS TO SYNTHETISE THEM, COMPOSITION CONTAINING THEM AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1993-09-01 EP claimed
EP-0373549-A2 Amino acid derivatives with enzyme-inhibiting properties, process to synthetise them, composition containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1990-06-20 EP claimed
EP-0370454-A2 Renin-inhibiting amino diol derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1990-05-30 EP claimed
EP-2121636-B1 PROCESS FOR THE PREPARATION OF PIPERAZINYL AND DIAZEPANYL BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-01-25 EP disclosed
US-9434730-B2 PDE1 inhibitor compounds INTRA-CELLULAR THERAPIES, INC. (US) 2016-09-06 US disclosed
WO-2016087593-A1 NOVEL FUNGICIDAL QUINOLINYLAMIDINES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 WO disclosed
EP-2367431-B1 ORGANIC COMPOUNDS INTRA CELLULAR THERAPIES INC (US) 2015-08-05 EP disclosed
US-20140315868-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2014-10-23 US disclosed
US-8697710-B2 Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones INTRA-CELLULAR THERAPIES, INC. (US) 2014-04-15 US disclosed
US-8680273-B2 Process for the preparation of piperazinyl and diazepanyl benzamide derivatives JANSSEN PHARMACEUTICA NV (BE) 2014-03-25 US disclosed
US-20130338124-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2013-12-19 US disclosed
WO-2002012214-A2 NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS ORTHO MCNEIL PHARMACEUTICAL INC. (US) 2002-02-14 WO disclosed
WO-2002012190-A2 NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-02-14 WO disclosed
WO-2002012224-A2 BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-02-14 WO disclosed
US-5360791-A Renin-inhibiting aminodiol derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1994-11-01 US disclosed
EP-0373549-B1 AMINO ACID DERIVATIVES WITH ENZYME-INHIBITING PROPERTIES, PROCESS TO SYNTHETISE THEM, COMPOSITION CONTAINING THEM AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1993-09-01 EP disclosed
US-5185324-A ENZYME-INHIBITING AMINO ACID DERIVATIVES, A PROCESS FOR THE PREPARATION THEREOF, AGENTS CONTAINING THESE, AND THE USE THEREOF HOECHST AKTIENGESELLSCHAFT (DE) 1993-02-09 US disclosed
EP-0373549-A2 Amino acid derivatives with enzyme-inhibiting properties, process to synthetise them, composition containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1990-06-20 EP disclosed
EP-0370454-A2 Renin-inhibiting amino diol derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1990-05-30 EP disclosed
US-3979380-A INOTROPIC ACTIVITY, CARDIAC STIMULANTS AMERICAN HOME PRODUCTS CORPORATION (US) 1976-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315868-A1 ORGANIC COMPOUNDS TPMT, CYP4X1, P2RX4 HSD17B10 3599/4885LMNA 4730/4885MAPT 942/4885
US-20130338124-A1 ORGANIC COMPOUNDS OPRD1, PDE5A, PDE2A HSD17B10 678/4885LMNA 4221/4885MAPT 1496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.